The Role of the Amylin Analogue Cagrilintide in Bone Metabolism — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism — Stella

Recruiting

Back to Obesity trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Denmark

Steno Diabetes Center Copenhagen, Herlev

Key details

Phase

Early testing

Sponsor

Novo Nordisk A/S

Enrollment target

~144 participants

Started

June 2025

Primary completion

May 2028

Age range

50 Years – 70 Years

Sex

Female only

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov